Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Clinical Attachment Loss

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43893   clinical trials with a EudraCT protocol, of which   7300   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    17 result(s) found for: Clinical Attachment Loss. Displaying page 1 of 1.
    EudraCT Number: 2019-003541-15 Sponsor Protocol Number: 2019-Fungi Start Date*: 2020-02-19
    Sponsor Name:Aarhus University
    Full Title: Adjunct effect of fluconazole in the treatment of Candida-associated refractory severe periodontitis – A single-center, placebo-controlled, triple blind, randomized clinical trial
    Medical condition: Periodontitis. The participants are in good general health, but have at least 2 residual dental lesions after periodontal treatment (standard care).
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004862 10009102 Chronic periodontitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-004493-34 Sponsor Protocol Number: 2017/06NOV/503 Start Date*: 2018-01-02
    Sponsor Name:Cliniques universitaires Saint-Luc
    Full Title: Evaluation of multiple subgingival irrigations with 10% povidone iodine after scaling and root planing : a randomized clinical trial
    Medical condition: Periodontitis is characterized by alveolar bone loss induced by the host immune response to bacterial insult. Because povidone iodine is known to be a powerful antiseptic, there is biologic rationa...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-000741-39 Sponsor Protocol Number: 6996 Start Date*: 2019-11-07
    Sponsor Name:Hôpitaux Universitaires de Strasbourg
    Full Title: EFFECT OF AZITHROMYCIN ON THE PROPORTION OF FAILURES OF SEVERE PERIODONTITIS NON-SURGICAL TREATMENTS : A RANDOMIZED, DOUBLE-BLIND VERSUS PLACEBO STUDY
    Medical condition: Periodontology
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2006-001367-36 Sponsor Protocol Number: DoxP-01/2006 Start Date*: 2006-12-05
    Sponsor Name:Prof. Dr. Peter Eickholz
    Full Title: Benefit of adjunctive systemic postsurgical doxycycline in regenerative periodontal surgery
    Medical condition: Periodontitis is an opportunistic infectious disease that destroys the periodontal attachment and bone. Bacterial plaque (biofilm) on the teeth adjacent to the gingiva is the necessary cause gingiv...
    Disease: Version SOC Term Classification Code Term Level
    8.1 10034539 Periodontitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2007-005660-27 Sponsor Protocol Number: OP-P-5265-1 Start Date*: 2008-02-13
    Sponsor Name:OraPharma Inc.
    Full Title: Multi-Center Phase 3 Trial of Minocycline HCl 1mg Microspheres for the Use in Subjects with Peri-Implantitis
    Medical condition: peri-implantitis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10034539 Periodontitis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-020404-29 Sponsor Protocol Number: H9V-MC-GFRF Start Date*: 2011-04-08
    Sponsor Name:Eli Lilly and Company Limited, Indianapolis
    Full Title: A Randomized, Double-Masked, Placebo-Controlled, Multicenter, Phase 2 Study to Evaluate the Safety and Renal Efficacy of LY2382770 in Patients with Diabetic Kidney Disease due to Type 1 or Type 2 D...
    Medical condition: Patients with Diabetic Kidney Disease due to Type 1 or Type 2 Diabetes
    Disease: Version SOC Term Classification Code Term Level
    15.0 10038359 - Renal and urinary disorders 10064848 Chronic kidney disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Prematurely Ended) CZ (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-004724-11 Sponsor Protocol Number: 294568 Start Date*: 2014-09-22
    Sponsor Name:Karolinska Institute
    Full Title: Surgical treatment of peri-implantitis with and without systemically adjunctive antibiotics A prospective, open, randomized, three armed, parallel, placebo controlled clinical trial
    Medical condition: peri-implantitis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-010830-23 Sponsor Protocol Number: H8O-EW-GWDL Start Date*: 2009-08-21
    Sponsor Name:Eli Lilly and Company Limited
    Full Title: Efficacy of Once-Weekly Exenatide versus Once or Twice Daily Insulin Detemir in Patients with Type 2 Diabetes Treated with Metformin Alone or in Combination with Sulphonylurea
    Medical condition: Diabetes
    Disease: Version SOC Term Classification Code Term Level
    14.0 10027433 - Metabolism and nutrition disorders 10012594 Diabetes LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) IE (Completed)
    Trial results: View results
    EudraCT Number: 2007-003392-39 Sponsor Protocol Number: M/31416/51 Start Date*: 2008-02-06
    Sponsor Name:Laboratorios Almirall SA
    Full Title: Standardized sTudy with Almotriptan in eaRly Treatment of migraine, START. An international, open-label, single arm, effectiveness and safety study of Almotriptan in primary care seeting.
    Medical condition: Migraine
    Disease:
    Population Age: Gender: Male, Female
    Trial protocol: FR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2016-000634-21 Sponsor Protocol Number: 64304500CRD2001 Start Date*: 2016-11-08
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A Phase 2b, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Protocol to Evaluate the Safety and Efficacy of JNJ-64304500 in Subjects with Moderately to Severely Active Cro...
    Medical condition: Active Crohn's Disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 10017947 - Gastrointestinal disorders 10011401 Crohn's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (GB - no longer in EU/EEA) HU (Completed) PL (Completed) FR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2009-015953-18 Sponsor Protocol Number: DORIPED3002 Start Date*: 2010-05-28
    Sponsor Name:Janssen-Cilag International NV, Turnhoutseweg 30, 2340 Beerse, Belgium
    Full Title: A Prospective, Randomized, Double-Blind, Multicenter Study to Establish the Safety and Tolerability of Doripenem Compared With Cefepime in Hospitalized Children With Complicated Urinary Tract Infec...
    Medical condition: Complicated Urinary Tract Infections
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021881 - Infections and infestations 10046571 Urinary tract infection PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: LT (Prematurely Ended) CZ (Completed) PL (Temporarily Halted) LV (Prematurely Ended) DE (Completed) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2010-020380-20 Sponsor Protocol Number: R331333-PAI2005/KF5503-59 Start Date*: 2012-03-09
    Sponsor Name:Janssen Research & Development, L.L.C.
    Full Title: Open-Label Evaluation of the Pharmacokinetic Profile and Safety of Tapentadol Oral Solution for the Treatment of Postsurgical Pain in Children and Adolescents Aged From 6 to Less Than 18 Years
    Medical condition: Pain
    Disease: Version SOC Term Classification Code Term Level
    14.1 10018065 - General disorders and administration site conditions 10033371 Pain PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA ES (Completed)
    Trial results: View results
    EudraCT Number: 2019-000648-86 Sponsor Protocol Number: OPN-FLU-CS-3206 Start Date*: 2019-10-01
    Sponsor Name:OptiNose US, Inc.
    Full Title: A 24-Week Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study Evaluating the Efficacy and Safety of Intranasal Administration of 186 and 372 μg of OPN-375 Twice a Day (B...
    Medical condition: Chronic rhinosinusitis
    Disease: Version SOC Term Classification Code Term Level
    20.1 10021881 - Infections and infestations 10009137 Chronic sinusitis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) CZ (Completed) PL (Completed) ES (Ongoing) BG (Completed) RO (Ongoing)
    Trial results: View results
    EudraCT Number: 2008-004330-24 Sponsor Protocol Number: H3E-MC-S104 Start Date*: 2009-02-20
    Sponsor Name:Eli Lilly and Company
    Full Title: A Phase 2 Study of Pemetrexed and Cisplatin plus Cetuximab followed by Pemetrexed and Cetuximab Maintenance Therapy in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer (Stage...
    Medical condition: Locally Advanced or Metastatic Non-Small Cell Lung Cancer (Stage IIIB or IV) other than Predominantly Squamous Cell Histology
    Disease: Version SOC Term Classification Code Term Level
    9.1 10025055 Lung cancer non-small cell stage IV LLT
    9.1 10025054 Lung cancer non-small cell stage IIIB LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed) NL (Completed) ES (Completed) IT (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2008-004837-54 Sponsor Protocol Number: RABGRD3003 Start Date*: 2009-03-05
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A Multicenter, Double-Blind, Parallel-Group Study to Evaluate Short-Term Safety and Efficacy and Long-Term Maintenance of Two Dose Levels of Rabeprazole Sodium Delayed-Release Pediatric Bead Formul...
    Medical condition: Endoscopically proven gastroesophageal reflux disease (GERD) in a paediatric population of 1 to 11 year old subjects.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10018203 GERD LLT
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: DK (Completed) BE (Completed) FR (Completed) NL (Ongoing) IT (Completed) BG (Not Authorised)
    Trial results: View results
    EudraCT Number: 2009-010739-42 Sponsor Protocol Number: H6D-MC-LVID Start Date*: 2009-10-01
    Sponsor Name:Eli Lilly and Company
    Full Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Design, Global Multicenter Study to Evaluate the Efficacy and Safety of Tadalafil Once Daily Dosing for 12 Weeks in Men with Signs ...
    Medical condition: Benign Prostatic Hyperplasia (BPH)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10004446 Benign prostatic hyperplasia LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: DE (Completed) NL (Completed) BE (Completed) AT (Completed) IT (Completed) FR (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2009-014803-30 Sponsor Protocol Number: H9X-MC-GBDB Start Date*: 2010-06-09
    Sponsor Name:Lilly S.A.
    Full Title: Estudio abierto, aleatorizado, con dos ramas paralelas, comparativo de no inferioridad de los efectos de dos dosis de LY2189265 versus insulina glargina sobre el control glucémico en pacientes con ...
    Medical condition: Diabetes Mellitus tipo 2
    Disease: Version SOC Term Classification Code Term Level
    12.0 10012601 Diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) SE (Completed) FR (Completed) HU (Completed) SK (Completed) CZ (Completed) BE (Completed) GR (Completed) IT (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu May 30 04:55:05 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA